Would Janus' view on HDL be useful?
- Resource Type
- Authors
- S Oravec; M Kasko; V Kasko
- Source
- Bratislavske lekarske listy. 119(4)
- Subject
- Economics and Econometrics
030209 endocrinology & metabolism
030204 cardiovascular system & hematology
Bioinformatics
03 medical and health sciences
chemistry.chemical_compound
Therapeutic approach
0302 clinical medicine
Pathognomonic
Materials Chemistry
Media Technology
Medicine
Humans
Routine clinical practice
Pathological
Lipoprotein cholesterol
Dyslipidemias
Hypolipidemic Agents
Cholesterol
business.industry
Cholesterol, HDL
Forestry
Cholesterol, LDL
Atherosclerosis
chemistry
Cardiovascular Diseases
lipids (amino acids, peptides, and proteins)
business
Lipoprotein
- Language
- ISSN
- 0006-9248
Low-density lipoprotein cholesterol (LDL-C) is generally considered to be pro-atherogenic and high-density lipoprotein cholesterol (HDL-C) to be anti-atherogenic. The clinical approach to the diagnostics and treatment of clinical manifestations of atherosclerosis is the examination of the lipid spectrum. In routine clinical practice, the effects of the HDL class are measured only by determining the concentration of HDL cholesterol. It is questionable whether this clinical approach provides sufficient information to evaluate both the overall cardiovascular risk and the effect of hypolipidemic therapy. Recent studies revealed a shift from large to small HDL particles within the HDL family in the state of atherosclerotic cardiovascular diseases (CVD). This trend of lipoprotein constellation seems to be pathognomonic for dysfunctional lipoprotein profile under pathological state of the cardiovascular system. Thus, the diagnostic and therapeutic approach based on "good" cholesterol concept needs remedying (Fig. 1, Ref. 28).